Edition:
United States

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

25.44USD
12:07pm EDT
Change (% chg)

$0.32 (+1.27%)
Prev Close
$25.12
Open
$25.64
Day's High
$25.64
Day's Low
$24.70
Volume
23,223
Avg. Vol
68,539
52-wk High
$40.56
52-wk Low
$19.32

Select another date:

Tue, Apr 24 2018

BRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of Omaveloxolone

* REATA ANNOUNCES NEW PRECLINICAL DATA DEMONSTRATING THE POTENTIAL OF OMAVELOXOLONE IN THE TREATMENT OF FRIEDREICH’S ATAXIA AND OTHER SEVERE NEUROLOGICAL DISEASES Source text for Eikon: Further company coverage:

BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome

* REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

BRIEF-Reata Announces That Kyowa Hakko Kirin Received Sakigake Priority Review Designation For Bardoxolone Methyl In Japan

* REATA ANNOUNCES THAT KYOWA HAKKO KIRIN RECEIVED SAKIGAKE PRIORITY REVIEW DESIGNATION FOR BARDOXOLONE METHYL IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial

* REATA ANNOUNCES POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WITH BARDOXOLONE METHYL FROM THE PHASE 2 LARIAT TRIAL

BRIEF-Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64

* REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Reata Announces Top-Line Data From Study Of Patients With Mitochondrial Myopathies

* REATA ANNOUNCES TOP-LINE DATA FROM THE DOSE-ESCALATION COHORTS OF THE PHASE 2 MOTOR STUDY OF OMAVELOXOLONE IN PATIENTS WITH MITOCHONDRIAL MYOPATHIES Source text for Eikon: Further company coverage:

BRIEF-Reata Provides Program Update On Phase 2 Rare Renal Clinical Trials

* REATA PROVIDES PROGRAM UPDATE ON PHASE 2 RARE RENAL CLINICAL TRIALS

BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial

* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​

* Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing Source text : (http://bit.ly/2AG2XNP) Further company coverage:

Select another date: